About The Study: In this post hoc secondary analysis of 10,678 participants with atherosclerotic cardiovascular disease from a randomized clinical trial, enteric-coated aspirin was not associated with significantly higher risk of heart attack, stroke, or death or with lower bleeding risk compared with uncoated aspirin, regardless of dose, although a reduction in bleeding with enteric-coated aspirin cannot be excluded. More research is needed to confirm whether enteric-coated aspirin formulations or newer formulations will improve outcomes in this population.
Authors: Mark B. Effron, M.D., of the University of Queensland-Ochsner Clinical School in New Orleans, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamacardio.2023.3364)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflicts of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamacardiology/fullarticle/10.1001/jamacardio.2023.3364?guestAccessKey=bb07ae80-e9a3-46a8-95a7-faff2ca16b5a&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=100423
JAMA Cardiology